Testing of CpG-optimized protein and DNA vaccines against the hepatitis B virus in chimpanzees for immunogenicity and protection from challenge

Intervirology

Volumn 49, Issue 3, 2006, Pages 144-151

  Payette, Paul J ^a   Ma, Xiaoying ^a   Weeratna, Risini D ^a   McCluskie, Michael J ^a   Shapiro, Max ^b   Engle, Ron E ^c   Davis, Heather L ^a   Purcell, Robert H ^c  

^a Coley Pharmaceutical Canada ^*  (Canada)

^b BIOQUAL INC   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Chimpanzees; CpG motifs; CpG ODN; HBV vaccines; Plasmid DNA

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; PLASMID VECTOR; RECOMBINANT HEPATITIS B VACCINE;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CHIMPANZEE; CONTROLLED STUDY; CPG ISLAND; HEPATITIS B; HEPATITIS B VIRUS; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOSTIMULATION; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; OLIGODEOXYRIBONUCLEOTIDES; PAN TROGLODYTES; VACCINES, DNA; VACCINES, SYNTHETIC;

ANIMALIA; HEPATITIS B VIRUS; PAN; PAN TROGLODYTES; PRIMATES;

EID: 31144441904     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089375     Document Type: Article

References (28)

1. Lee WM: Hepatitis B virus infection. N Engl J Med 1997;337:1733-1745.
2. World Health Organization: Thirteenth meeting of the Global Advisory Group of EPI. 1-2 3-7-3/9-12. Weekly Epidemiological Record. World Health Organization, 1992.
3. Maddrey WC: Hepatitis B: an important public health issue. J Med Virol 2000;61:362-366.
4. Krieg AM: CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002;20:709-760.
5. Krieg AM, Davis HL: Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Ther 2001;3:15-24.
6. Davis HL, Suparto II, Weeratna RR, Jumintarto, Iskandriati DD, Chamzah SS, et al: CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 2000;18:1920-1924.
7. Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM, et al: CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 1998;160:870-876
8. (published erratum appears in J Immunol 1999;162:3103).
9. Weeratna RD, McCluskie MJ, Xu Y, Davis HL: CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 2000;18:1755-1762.
10. McCluskie MJ, Weeratna RD, Davis HL: The role of CpG in DNA vaccines. Springer Semin Immunopathol 2000;22:125-132.
11. Krieg AM, Wu T, Weeratna R, Efler SM, Love-Homan L, Yang L, et al: Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci USA 1998;95:12631-12636.
12. Davis HL, Michel ML, Whalen RG: DNA based immunization for hepatitis B induces continuous secretion of antigen and high levels of circulating antibody. Hum Mol Genet 1993;2:1847-1851.
13. Davis HL, McCluskie MJ, Gerin JL: Purcell RH. DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc Natl Acad Sci USA 1996;93:7213-7218.
14. Pas SD, Fries E, De Man RA, Osterhaus AD, Niesters HG: Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol 2000;38:2897-2901.
15. Hall TA: BioEdit: a user friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 1999;41:95-98.
16. Saldanha J, Gerlich W, Lelie N, Dawson P, Heermann K, Heath A: An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang 2001;80:63-71.
17. Tabor E, Purcell RH, London WT, Gerety RJ: Use of and interpretation of results using inocula of hepatitis B virus with known infectivity titers. J Infect Dis 1983;147:531-534.
18. Prince AM, Whalen R, Brotman B: Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus. Vaccine 1997;15:916-919.
19. Gramzinski RA, Millan CL, Obaldia N, Hoffman SL, Davis HL: Immune response to a hepatitis B DNA vaccine in Aotus monkeys: a comparison of vaccine formulation, route, and method of administration. Mol Med 1998;4:109-118.
20. Gurunathan S, Klinman DM, Seder RA: DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 2000;18:927-974.
21. McCluskie MJ, Brazolot Millan CL, Gramzinski RA, Robinson HL, Santoro JC, Fuller JT, et al: Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol Med 1999;5:287-300.
22. + T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003;77:68-76.
23. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, et al: Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 2000;164:1617-1624.
24. Hartmann G, Weiner GJ, Krieg AM: CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci USA 1999;96:9305-9310.
25. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546-549.
26. Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM, et al: CpG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B® HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 2004;24:693-701.
27. Cooper CL, Davis HL, Angel JB, Morris ML, Efler SM, Sequin I, et al: CpG 7909 is safe and highly effective as an adjuvant to HBV vaccine in HIV serpositive adults. Aids, in press.
28. Halperin SA, Van Nest G, Smith B, Abtahi S, Whiley H, Eiden JJ: A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 2003;21:2461-2467.